HCW Biologics Regains Full Rights to CAR-T Reagents from Wugen

HCW Biologics exercised its option to regain exclusive ex vivo rights to HCW9206 and HCW9201 compounds from Wugen at no cost while retaining upfront fees including 2.2M Wugen shares. The move positions the company to commercialize CAR-T manufacturing reagents that published data suggests may reduce production costs and improve therapeutic efficacy in the multi-billion-dollar immunotherapy market.